Small Lymphocytic Lymphoma

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) [Phase 3]

  A Phase 3 study CELESTIAL-RRCLL is evaluating progression-free survival with Sonrotoclax in combination with Obinutuzumab or Rituximab, vers…

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

  This clinical trial update describes a Phase 3 study comparing the safety and efficacy of BGB-16673 versus Pirtobrutinib in adults with rela…

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors [Phase 3]

  A Phase 3 clinical trial comparing BGB-16673 to investigator's choice in chronic lymphocytic leukemia or small lymphocytic lymphoma patients…

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma [Phase 2]

  This clinical trial update describes a Phase 2 study of a triple therapy (Sonrotoclax, Rituximab, and Zanubrutinib) for chronic lymphocytic …

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]

  This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study [Phase 3]

  The EVOLVE CLL/SLL study is a Phase 3 clinical trial sponsored by the National Cancer Institute to evaluate early treatment in patients with…

• CLINICAL_TRIALS trial_result · 2026-04-22
  Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors [Phase 3]

  A Phase 3 study evaluating BGB-16673 versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic l…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]

  This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

  Phase 3 trial comparing pirtobrutinib (LOXO-305) to ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. T…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

  Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…

• CLINICAL_TRIALS research · 2026-04-20
  Clinical Trial Update: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

  A Phase 2 clinical trial update evaluating nemtabrutinib and lisocabtagene maraleucel for relapsed/refractory chronic lymphocytic leukemia a…

• CLINICAL_TRIALS trial_result · 2026-04-17
  Clinical Trial Update: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL [Phase 1, Phase 2]

  Phase I/II clinical trial update describing the study of Rapcabtagene Autoleucel in chronic lymphocytic leukemia, small lymphocytic lymphoma…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]

  Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 4]

  A Phase 4 trial evaluating pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) [Phase 2]

  A Phase 2 clinical trial (DAYBreak CLL-201) evaluating NX-5948 in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who…

• CLINICAL_TRIALS trial_result · 2026-04-14
  Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]

  NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating acalabrutinib and venetoclax with or without early obinutuzumab for high-risk, recurrent, or refractory ch…

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

  This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia [Phase 3]

  This clinical trial update describes a Phase 3 study evaluating whether combining venetoclax with other therapy can enable time-limited trea…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the safety and efficacy of epcoritamab in subjects with relapsed/refractory chronic lymphocytic leukem…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL [Phase 2]

  A Phase 2 clinical trial at Massachusetts General Hospital is evaluating venetoclax and obinutuzumab with or without acalabrutinib in relaps…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]

  A Phase 1 clinical trial update investigating a combination of lenalidomide, ibrutinib, and rituximab for relapsed or refractory chronic lym…

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]

  Phase 2 trial update for customizing ibrutinib treatment regimens in previously untreated chronic lymphocytic leukemia and small lymphocytic…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies [Phase 1, Phase 2]

  AstraZeneca is evaluating AZD0486 as a monotherapy or in combination with other anticancer agents for mature B-cell malignancies in Phase 1/…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors [Phase 2]

  A Phase 2 clinical trial update examining treatment outcome patterns for patients with chronic lymphocytic leukemia or small lymphocytic lym…